Latest News and Press Releases
Want to stay updated on the latest news?
-
Important Milestone for European Phase III Trial Triggers 9-Month Follow-Up Period Data Readout Expected in the Middle of 2016 MONT-SAINT-GUIBERT, Belgium, Aug. 3, 2015 (GLOBE NEWSWIRE) --...
-
MONT-SAINT-GUIBERT, Belgium, June 24, 2015 (GLOBE NEWSWIRE) -- Celyad SA (formerly known as Cardio3 BioSciences) (Euronext Brussels:CYAD) (Paris:CYAD), announced today the closing of its global...
-
MONT-SAINT-GUIBERT, Belgium, June 18, 2015 (GLOBE NEWSWIRE) -- Celyad SA (formerly known as Cardio3 BioSciences) (Euronext Brussel:CYAD) (Paris:CYAD), today announced the pricing of its global...
-
MONT-SAINT-GUIBERT, Belgium, June 15, 2015 (GLOBE NEWSWIRE) -- Celyad SA (formerly known as Cardio3 BioSciences) (Brussels:CYAD) (Paris:CYAD), today announced that it intends to offer and sell,...
-
No Treatment-Related Safety Concerns Reported No safety issues related to the investigational treatment reported at 30 days post treatment of the first patient following single dose NKG2D CAR...
-
MONT-SAINT-GUIBERT, Belgium, May 19, 2015 (GLOBE NEWSWIRE) -- Celyad (formerly known as Cardio3 BioSciences, Euronext Brussels and Paris: CYAD), a leader in the discovery and development of engineered...
-
MONT-SAINT-GUIBERT, Belgium, May 18, 2015 (GLOBE NEWSWIRE) -- Celyad SA (formerly known as Cardio3 BioSciences) (Brussels:CYAD) (Paris:CYAD), a leader in the discovery and development of engineered...
-
MONT-SAINT-GUIBERT, Belgium, May 5, 2015 (GLOBE NEWSWIRE) -- Cardio3 BioSciences ("the Company") (Brussels:CARD) (Paris:CARD) a leader in the discovery and development of engineered cell therapies,...
-
No short term on-target, off-tumor toxicity observed to date in first patient following single dose NKG2D CAR T-cell infusion; marks an important step in therapy evaluation. Staggered...
-
MONT-SAINT-GUIBERT, Belgium, April 15, 2015 (GLOBE NEWSWIRE) -- Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of engineered cell therapies,...